Patient Direct Model Will Transform Home-Based Health Care Market

Key Takeaways

• Focusing on higher-margin home-based care and divesting lower-growth segments enhances long-term growth, margin expansion, and free cash flow.
  
• Investments in technology, operational efficiency, and targeted acquisitions improve profitability and support ongoing balance sheet strengthening.
  
• Divestiture, slow revenue growth, contract losses, high debt, and healthcare shifts threaten margins, earnings, and long-term growth for Owens & Minor's Patient Direct business.

Catalysts

Operates as a healthcare solutions company worldwide.

• The shift to a pure-play Patient Direct model, focusing solely on higher-growth, higher-margin home-based care, positions Owens & Minor to capitalize on demographic trends such as the aging population and increased prevalence of chronic diseases, supporting long-term, sustainable revenue growth and margin expansion.
  
• Expansion in the home-based care market-bolstered by growing demand for treatment of chronic conditions outside the traditional hospital setting-provides a sustained tailwind for volume growth and net earnings as more patients require at-home medical supplies and services.
  
• Ongoing investments in IT infrastructure, supply chain automation, and enhanced revenue cycle management are driving operational efficiencies, already evidenced by improved collection rates and reduced working capital needs, which are expected to positively impact earnings and net margins over time.
  
• Strategic M&A, even if focused on smaller add-on acquisitions, remains a future catalyst, enabling scale, category expansion, and EBITDA growth, notably as freed-up cash flow from divestitures is prioritized for debt reduction and future deal flexibility.
  
• The process of divesting the lower-growth, lower-margin Products & Healthcare Services segment and redeploying proceeds to reduce debt will improve the balance sheet, lower interest expense, and create greater capacity for long-term investment, benefiting free cash flow and net income.

Owens & Minor Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Accendra Health's revenue will grow by 2.4% annually over the next 3 years.
• Analysts are not forecasting that Accendra Health will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Accendra Health's profit margin will increase from -3.9% to the average US Healthcare industry of 6.2% in 3 years.
• If Accendra Health's profit margin were to converge on the industry average, you could expect earnings to reach $179.8 million (and earnings per share of $2.41) by about June 2029, up from -$105.3 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 2.7x on those 2029 earnings, up from -2.0x today. This future PE is lower than the current PE for the US Healthcare industry at 23.2x.
• Analysts expect the number of shares outstanding to decline by 0.86% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 12.46%, as per the Simply Wall St company report.

Risks

• Owens & Minor's divestiture to become a pure-play Patient Direct business will lead to elevated stranded costs due to lost economies of scale and transitional expenses; these could weigh heavily on EBITDA margins and net earnings for several quarters after the sale, especially if cost reduction lags or proves more challenging than expected.
  
• Slower trajectory in core Patient Direct revenue growth, as indicated by recent quarterly deceleration (even with positive category mentions), could signal that underlying market expansion is not as strong as demographic trends imply, creating risk of longer-term revenue stagnation or insufficient top-line acceleration.
  
• Customer contract losses (such as the transition of the Kaiser contract referenced on the call), and increasing provider consolidation, threaten revenue stability and negotiating leverage for Patient Direct, potentially compressing gross margins due to lost scale or more competitive pricing requirements.
  
• High debt burden post-divestiture (with $1.9B in net debt and significant interest costs continuing even after discontinued operations), compounded by cash outflows from failed acquisitions (like the terminated Rotech deal), limits flexibility for growth investments and could dampen net income, especially if EBITDA does not scale as anticipated.
  
• Ongoing shifts in healthcare delivery and reimbursement (e.g., from DME to pharmacy in diabetes, future competitive bidding, and regulatory changes) increase the risk of structural margin compression or lost market share for Patient Direct, especially if key revenue streams migrate to lower-margin channels or direct-to-provider models, ultimately constraining net margins and earnings power.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $4.49 for Accendra Health based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $6.0, and the most bearish reporting a price target of just $2.7.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $2.9 billion, earnings will come to $179.8 million, and it would be trading on a PE ratio of 2.7x, assuming you use a discount rate of 12.5%.
• Given the current share price of $2.77, the analyst price target of $4.49 is 38.3% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.